J Fernando Arevalo1, Andres F Lasave2, Lihteh Wu3, Dhariana Acon3, Michel E Farah4, Roberto Gallego-Pinazo5, Arturo A Alezzandrini6, Veronica Fortuna6, Hugo Quiroz-Mercado7, Guillermo Salcedo-Villanueva7, Mauricio Maia4, Martin Serrano8, Sergio Rojas9. 1. Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 2. Retina and Vitreous Service, Clínica Privada de Ojos, Mar del Plata, Argentina. 3. Retina Service, Instituto de Cirugia Ocular, San Jose, Costa Rica. 4. Retina Division, Retina Division, Department of Ophthalmology and Visual Sciences, Federal University of Sao Paulo (UNIFESP), Sao Paulo, Brazil. 5. Department of Ophthalmology, Consorcio Hospital, General Universitario de Valencia, Valencia, Spain. 6. Facultad de Medicina, OFTALMOS, Universidad de Buenos Aires, Buenos Aires, Argentina. 7. Department of Ophthalmology, University of Colorado School of Medicine, Denver, Colorado, USA. 8. Retina Service, Clinica Oftalmologica Centro Caracas and the Arevalo-Coutinho Foundation for Research in Ophthalmology, Caracas, Venezuela. 9. Retina Service, Fundación Hospital Nuestra Señora de la Luz, Mexico City, Mexico.
Abstract
BACKGROUND/AIMS: To report the long-term anatomical and functional outcomes of patients with centre-involved diabetic macular oedema (DME) treated with intravitreal bevacizumab (IVB). METHODS: Retrospective case series. Patients diagnosed with centre-involved DME that were treated with at least one injection of 1.25 mg IVB and had a minimum follow-up of 60 months. Patients underwent measurement of best-corrected visual acuity (BCVA), ophthalmoscopy, optical coherence tomography and fluorescein angiography at baseline, 6-month, 12-month, 24-month, 36-month, 48-month and 60-month visits. The paired samples t test was used to compare the central macular thickness (CMT) and BCVA with baseline values. Statistical significance was indicated by p<0.05. RESULTS: Two hundred and one consecutive patients (296 eyes) were included. The mean number of IVB injections per eye was 8.4±7.1 (range: 1-47 injections). At 5 years, the BCVA remained stable at 20/100 (logarithm of the minimum angle of resolution=0.7±0.4). Eighty-six (29%) eyes improved ≥2 lines of BCVA, 129 (43.6%) eyes remained stable and 81 (27.4%) eyes lost ≥2 lines of BCVA at 60 months. Mean CMT decreased from 403.5±142.2 μm at baseline to 313.7±117.7 μm over 5 years follow-up (p≤0.0001). CONCLUSIONS: The early visual gains due to IVB were not maintained 5 years after treatment. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
BACKGROUND/AIMS: To report the long-term anatomical and functional outcomes of patients with centre-involved diabetic macular oedema (DME) treated with intravitreal bevacizumab (IVB). METHODS: Retrospective case series. Patients diagnosed with centre-involved DME that were treated with at least one injection of 1.25 mg IVB and had a minimum follow-up of 60 months. Patients underwent measurement of best-corrected visual acuity (BCVA), ophthalmoscopy, optical coherence tomography and fluorescein angiography at baseline, 6-month, 12-month, 24-month, 36-month, 48-month and 60-month visits. The paired samples t test was used to compare the central macular thickness (CMT) and BCVA with baseline values. Statistical significance was indicated by p<0.05. RESULTS: Two hundred and one consecutive patients (296 eyes) were included. The mean number of IVB injections per eye was 8.4±7.1 (range: 1-47 injections). At 5 years, the BCVA remained stable at 20/100 (logarithm of the minimum angle of resolution=0.7±0.4). Eighty-six (29%) eyes improved ≥2 lines of BCVA, 129 (43.6%) eyes remained stable and 81 (27.4%) eyes lost ≥2 lines of BCVA at 60 months. Mean CMT decreased from 403.5±142.2 μm at baseline to 313.7±117.7 μm over 5 years follow-up (p≤0.0001). CONCLUSIONS: The early visual gains due to IVB were not maintained 5 years after treatment. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Entities:
Keywords:
Macula; Neovascularisation; Posterior Chamber; Retina; Treatment Medical
Authors: Andreas Schicho; Claus Hellerbrand; Kristina Krüger; Lukas P Beyer; Walter Wohlgemuth; Christoph Niessen; Ernst Hohenstein; Christian Stroszczynski; Philippe L Pereira; Philipp Wiggermann Journal: J Clin Transl Hepatol Date: 2016-12-27
Authors: Francisco J Rodríguez; Lihteh Wu; Arnaldo F Bordon; Martin Charles; JinKyung Lee; Tobias Machewitz; Margarete Mueller; Gabriela Del Carmen Gay; Jans Fromow-Guerra Journal: Int J Retina Vitreous Date: 2022-08-02